Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.8800
-0.0320 (-3.51%)
At close: Jun 5, 2025, 4:00 PM
0.8611
-0.0189 (-2.15%)
After-hours: Jun 5, 2025, 6:55 PM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 4 employees as of December 31, 2024. The number of employees decreased by 4 or -50.00% compared to the previous year.
Employees
4
Change (1Y)
-4
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$3,401,746
Market Cap
6.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | -4 | -50.00% |
| Dec 31, 2023 | 8 | -7 | -46.67% |
| Dec 31, 2022 | 15 | 10 | 200.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
KTTA News
- 3 days ago - Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 - GlobeNewsWire
- 16 days ago - Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - GlobeNewsWire
- 22 days ago - Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site - GlobeNewsWire
- 4 weeks ago - Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga
- 4 weeks ago - Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewsWire
- 5 weeks ago - Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - GlobeNewsWire